Back to Search Start Over

Is a therapeutic dengue monoclonal antibody on the way?

Authors :
Ooi EE
Chan YF
Source :
The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Jun; Vol. 24 (6), pp. 567-568. Date of Electronic Publication: 2024 Feb 23.
Publication Year :
2024

Abstract

Competing Interests: EEO collaborated with Visterra, which developed VIS513 during the pre-clinical stages of development but was not involved with the clinical trial. EEO has also served in advisory capacities to Takeda on dengue vaccine, and Janssen Pharmaceuticals and Novartis on dengue therapeutics. YFZC declared no competing interests.

Subjects

Subjects :
Humans
Antibodies, Monoclonal therapeutic use
Dengue immunology
Dengue drug therapy
Antibodies, Viral therapeutic use
Dengue Virus immunology

Details

Language :
English
ISSN :
1474-4457
Volume :
24
Issue :
6
Database :
MEDLINE
Journal :
The Lancet. Infectious diseases
Publication Type :
Academic Journal
Accession number :
38408456
Full Text :
https://doi.org/10.1016/S1473-3099(24)00083-5
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details